Simcor

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Dyslipidemias (Dyslipidemia) 01/01/2008 - "The OCEANS study (Open-label evaluation of the safety and efficacy of a Combination of niacin ER and simvAstatin in patieNts with dySlipidemia; ClinicalTrials.gov identifier: NCT00080275) evaluated the safety and efficacy of a combination of niacin extended release and simvastatin (NER/S; SIMCOR) over 52 weeks in 520 patients with mixed dyslipidemia. "
2.	Flushing 09/01/2009 - "Extended-release nicotinic acid (or Niacin) remains the most effective pharmacological treatment currently available for elevating HDL-C, having recently been combined with simvastatin (as Simcor) and laropripant (as Cordaptive, to reduce flushing). "